发明名称 SRM ASSAY TO INDICATE CANCER THERAPY
摘要 The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the ALK, Ros, Ron, Ret, TS, and/or FGFRI proteins that are particularly advantageous for quantifying the ALK, Ros, Ron, Ret, TS, and/or FGFRI proteins directly in biological samples that have been fixed in formalin by the methods of Selected Reaction Monitoring (SRM) mass spectrometry, or as Multiple Reaction Monitoring (MRM) mass spectrometry.
申请公布号 CA2906965(A1) 申请公布日期 2014.09.18
申请号 CA20142906965 申请日期 2014.03.18
申请人 EXPRESSION PATHOLOGY, INC. 发明人 KRIZMAN, DAVID B.;HEMBROUGH, TODD;THYPARAMBIL, SHEENO;LIAO, WEI-LI
分类号 G01N33/574 主分类号 G01N33/574
代理机构 代理人
主权项
地址